(Q72182752)
Statements
Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report (English)
M Hussain
M Wolf
E Marshall
E D Crawford
1 September 1994